FDA Approves Pancreatic Enzyme CREON® as Part of Multi-product Review
| 1 min read

The U.S. Food and Drug Administration (FDA) has completed approval of CREON® (pancrelipase), the first pancreatic enzyme replacement therapy to be evaluated and approved under a new drug application (NDA) process for pancreatic enzymes. Pancreatic enzymes help people with cystic fibrosis and other conditions that involve exocrine pancreatic insufficiency to absorb nutrients, including fats, proteins and sugars.

The FDA is requiring all pancreatic enzyme replacement therapies currently on the market to be reformulated and undergo clinical testing in order to receive approval. The Cystic Fibrosis Foundation encouraged the FDA to mandate this NDA process to ensure that all pancreatic enzyme products are of the highest quality. Unapproved products will ultimately be removed from the market, helping to ensure that CF patients receive only products that are documented to be both safe and effective.

Companies currently completing clinical trials for NDA submission to the FDA include Axcan Pharma (Ultrase®), DCI (PANCRECARB®), Eurand (Zentase™) and McNeil (Pancrease MT).

Share this article
Topics
Research
Recent news
CF Foundation Reflects on Progress Toward Equity, Racial Justice, Diversity, and Inclusion
News | 4 min read
CF Foundation Invests Up to $3.5M in Gensaic for Novel Gene Delivery Method
News | 2 min read
CF Foundation Urges Vertex Pharmaceuticals to Reverse Consequential Decision on Copay Assistance
News | 3 min read
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.

Subscribe